SCPH Profile
scPharmaceuticals Inc., based in Burlington, Massachusetts, is a pharmaceutical company focused on the development and commercialization of advanced therapeutic products. The company’s primary emphasis is on innovative drug delivery systems designed to enhance patient outcomes and address critical healthcare needs. scPharmaceuticals is committed to advancing its product portfolio through cutting-edge technology and strategic partnerships.
The company’s lead product candidate is FUROSCIX, a formulation of furosemide delivered through an on-body infusor designed to treat congestion in patients with heart failure. This innovative delivery system allows for the continuous administration of furosemide, addressing a significant need for effective management of heart failure symptoms. FUROSCIX represents a key component of scPharmaceuticals' strategy to improve therapeutic options for patients with chronic conditions.
In addition to FUROSCIX, scPharmaceuticals is developing a range of other products aimed at addressing various medical conditions. Its pipeline includes scCeftriaxone, an antibiotic formulated to treat infections caused by both gram-positive and gram-negative organisms. The company is also advancing its scCarbapenem program, which focuses on antibiotics for treating infections caused by gram-negative bacteria. These products are designed to address growing concerns around antibiotic resistance and provide effective treatments for serious infections.
scPharmaceuticals has entered into a development agreement with West Pharmaceutical Services, Inc. to develop the SmartDose device, a single-use delivery system that complements its drug products. This collaboration underscores scPharmaceuticals' commitment to integrating innovative technology with its therapeutic offerings. Founded in 2013, scPharmaceuticals continues to expand its presence in the pharmaceutical industry, leveraging its expertise and partnerships to bring novel and effective treatments to market.
|
